China's Syneron raises $150M for peptides, adding to last year's $100M
manbetx3.0 元思生肽再获1.5亿美元用于多肽项目，继去年1亿美元之后再度加码

Syneron Bio said it raised a Series B round worth $150 million, which it will use to back the development of a drug class that’s attracted growing interest because of its potential to borrow some of the best characteristics of biologics and small molecules.
元思生肽表示已完成1.5亿美元的B轮融资，将用于推进一种药物类别的研发。由于这类药物有望兼具大分子生物药与小分子药的一些最佳特性，近来备受关注。